VYGR
VYGR
NASDAQ · Biotechnology

Voyager Therapeutics Inc

$3.96
-0.17 (-4.12%)
As of Mar 29, 10:34 PM ET ·
Financial Highlights (FY 2026)
Revenue
67.95M
Net Income
-55,206,702
Gross Margin
Profit Margin
-81.3%
Rev Growth
+28.9%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 40.1% 40.1%
Operating Margin -104.1% -93.7% -0.3% -0.3%
Profit Margin -81.3% -77.2% -0.3% -0.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 67.95M 52.73M 42.57M 38.58M
Gross Profit 17.06M 15.46M
Operating Income -70,738,142 -49,409,645 -137,767 -112,961
Net Income -55,206,702 -38,561,142 -129,666 -108,514
Gross Margin 40.1% 40.1%
Operating Margin -104.1% -93.7% -0.3% -0.3%
Profit Margin -81.3% -77.2% -0.3% -0.3%
Rev Growth +28.9% +28.9% +21.1% -3.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 56.86M 64.95M
Total Equity 186.28M 172.57M
D/E Ratio 0.31 0.38
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -66,187,311 -48,799,336 -158,434 -135,051
Free Cash Flow -114,389 -110,539